دورية أكاديمية
Validation of the Remote Automated ki:e Speech Biomarker for Cognition in Mild Cognitive Impairment: Verification and Validation following DiME V3 Framework
| العنوان: | Validation of the Remote Automated ki:e Speech Biomarker for Cognition in Mild Cognitive Impairment: Verification and Validation following DiME V3 Framework |
|---|---|
| المؤلفون: | Johannes Tröger, Ebru Baykara, Jian Zhao, Daphne ter Huurne, Nina Possemis, Elisa Mallick, Simona Schäfer, Louisa Schwed, Mario Mina, Nicklas Linz, Inez Ramakers, Craig Ritchie |
| المصدر: | Digital Biomarkers, Vol 6, Iss 3, Pp 107-116 (2022) |
| بيانات النشر: | Karger Publishers, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Biology (General) |
| مصطلحات موضوعية: | mild cognitive impairment, digital biomarker, speech biomarker, dementia, speech analysis, clinical trials, Biology (General), QH301-705.5 |
| الوصف: | Introduction: Progressive cognitive decline is the cardinal behavioral symptom in most dementia-causing diseases such as Alzheimer’s disease. While most well-established measures for cognition might not fit tomorrow’s decentralized remote clinical trials, digital cognitive assessments will gain importance. We present the evaluation of a novel digital speech biomarker for cognition (SB-C) following the Digital Medicine Society’s V3 framework: verification, analytical validation, and clinical validation. Methods: Evaluation was done in two independent clinical samples: the Dutch DeepSpA (N = 69 subjective cognitive impairment [SCI], N = 52 mild cognitive impairment [MCI], and N = 13 dementia) and the Scottish SPeAk datasets (N = 25, healthy controls). For validation, two anchor scores were used: the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating (CDR) scale. Results: Verification: The SB-C could be reliably extracted for both languages using an automatic speech processing pipeline. Analytical Validation: In both languages, the SB-C was strongly correlated with MMSE scores. Clinical Validation: The SB-C significantly differed between clinical groups (including MCI and dementia), was strongly correlated with the CDR, and could track the clinically meaningful decline. Conclusion: Our results suggest that the ki:e SB-C is an objective, scalable, and reliable indicator of cognitive decline, fit for purpose as a remote assessment in clinical early dementia trials. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2504-110X 00052647 |
| العلاقة: | https://www.karger.com/Article/FullText/526471Test; https://doaj.org/toc/2504-110XTest |
| DOI: | 10.1159/000526471 |
| الوصول الحر: | https://doaj.org/article/d715274c09c14aa5807f9200f2c82a8fTest |
| رقم الانضمام: | edsdoj.715274c09c14aa5807f9200f2c82a8f |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 2504110X 00052647 |
|---|---|
| DOI: | 10.1159/000526471 |